Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan J Thompson

Showing results (11-20 of 200) with videos related to

Pageof 20
Sort By:
Neurology|May 16, 2002
Cannabinoids in MS: potentially useful but not just yet!Alan J Thompson, David Baker
Neurology|November 13, 2013
Multiple Sclerosis International Federation: stimulating international cooperation in researchAlan J Thompson, Dhia Chandraratna
Neurology|January 30, 2025
Interpreting the Results of 9-Year Open-Label Extension of Ocrelizumab in Treatment-Naïve Patients With Relapsing MSOlga Ciccarelli, Alan J Thompson
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 11, 2020
Atlas of MS 2020: Informing global policy changeTimothy Coetzee, Alan J Thompson
Annals of Neurology|February 1, 2011
Dissecting the familial risk of multiple sclerosisJohn Hardy, Alan J Thompson
BMJ (Clinical Research Ed.)|January 22, 2013
Removal of access to alemtuzumab for patients with aggressive multiple sclerosisAlan J Thompson, Gavin Giovannoni
The Practitioner|November 24, 2015
Early accurate diagnosis crucial in multiple sclerosisCarmen Tur, Alan J Thompson
Nature Reviews. Neurology|January 13, 2018
Unified understanding of MS course is required for drug developmentTimothy Coetzee, Alan J Thompson
Neurology|September 10, 2003
Is multiple sclerosis still a clinical diagnosis?Jack H Simon, Alan J Thompson
CNS Drugs|May 24, 2005
Primary progressive multiple sclerosis : current and future treatment optionsSiobhan M Leary, Alan J Thompson
Pageof 20

Showing results (11-20 of 200) with videos related to

Sort By:
Pageof 20
Neurology|May 16, 2002
Cannabinoids in MS: potentially useful but not just yet!Alan J Thompson, David Baker
Neurology|November 13, 2013
Multiple Sclerosis International Federation: stimulating international cooperation in researchAlan J Thompson, Dhia Chandraratna
Neurology|January 30, 2025
Interpreting the Results of 9-Year Open-Label Extension of Ocrelizumab in Treatment-Naïve Patients With Relapsing MSOlga Ciccarelli, Alan J Thompson
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 11, 2020
Atlas of MS 2020: Informing global policy changeTimothy Coetzee, Alan J Thompson
Annals of Neurology|February 1, 2011
Dissecting the familial risk of multiple sclerosisJohn Hardy, Alan J Thompson
BMJ (Clinical Research Ed.)|January 22, 2013
Removal of access to alemtuzumab for patients with aggressive multiple sclerosisAlan J Thompson, Gavin Giovannoni
The Practitioner|November 24, 2015
Early accurate diagnosis crucial in multiple sclerosisCarmen Tur, Alan J Thompson
Nature Reviews. Neurology|January 13, 2018
Unified understanding of MS course is required for drug developmentTimothy Coetzee, Alan J Thompson
Neurology|September 10, 2003
Is multiple sclerosis still a clinical diagnosis?Jack H Simon, Alan J Thompson
CNS Drugs|May 24, 2005
Primary progressive multiple sclerosis : current and future treatment optionsSiobhan M Leary, Alan J Thompson
Pageof 20